GlassScriptPhysician profile
Mark Jeffery Mcnabb
NPI 1942337522
$3,707.67
in general payments reported to CMS, 2019-2025
33 companies · $490 in 2025
The $490 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $237 · 2021: $743 · 2022: $697 · 2023: $734 · 2024: $653 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,813 · Education: $64.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,813.12 |
| Education | $64.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,717.08 | 2021-2025 | |
| Lilly USA, LLC | $434.93 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $160.35 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Allergan, INC. | $141.44 | 2020 | |
| Astellas Pharma US INC | $119.60 | 2021-2023 | Veozah |
| Axsome Therapeutics, INC. | $104.24 | 2023-2024 | Sunosi |
| Astrazeneca Pharmaceuticals LP | $92.91 | 2023-2025 | Farxiga, Breztri |
| Dexcom, INC. | $92.36 | 2021-2025 | Dexcom G6 Transmitter |
| Verona Pharma, INC. | $90.57 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $82.10 | 2022-2023 | |
| Harmony Biosciences LLC | $80.01 | 2024 | |
| Phathom Pharmaceuticals, INC. | $61.45 | 2024-2025 | Voquezna |
| Pfizer INC. | $49.12 | 2019-2025 | |
| Abbott Laboratories | $46.38 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $39.73 | 2020-2023 | Spravato |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $38.23 | 2022 | |
| Merck Sharp & Dohme LLC | $36.18 | 2021 | |
| Idorsia Pharmaceuticals US INC | $32.70 | 2022-2023 | Quviviq |
| Sumitomo Pharma America, INC. | $32.54 | 2023-2024 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $31.58 | 2019-2021 | |
| Insulet Corporation | $25.12 | 2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $24.52 | 2023 | Gvoke Hypopen |
| Paratek Pharmaceuticals, INC. | $18.70 | 2024 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.12 | 2019 | |
| Apria Healthcare LLC | $17.94 | 2021 | |
| Eisai INC. | $17.66 | 2021 | |
| Medtronic, INC. | $16.98 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.74 | 2025 | Rexulti |
| Amgen INC. | $15.28 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.62 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.31 | 2023 | Seglentis, Livalo |
| Shield Therapeutics INC | $12.84 | 2023 | Accrufer |
| Edwards Lifesciences Corporation | $12.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mcnabb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.